Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TMI from TIMI: Xarelto and the Trouble with Very Large Trials

This article was originally published in RPM Report

Executive Summary

With bigger clinical trials come potentially bigger problems. That, at least, is what sponsors of 15,000-plus trials in cardiovascular medicine are finding out. J&J/Bayer’s experience in late May with Xarelto for acute coronary syndrome is a case in point—and it also provides timely context for the surprising setback for another CV project, Pfizer/BMS' Eliquis.

You may also be interested in...

J&J To Persevere In ACS After Another “Complete Response” For Xarelto

J&J says it remains confident about getting expanded approval for Xarelto after receiving a “complete response” letter from FDA for reducing risk of stent thrombosis in patients with acute coronary syndrome.

Whistleblower Management: Rogue FDA Reviewer Sets Tone to Start Avandia Committee; Forgotten By End

Avandia has been a contentious topic for FDA for six years. The latest advisory committee review highlights how far the agency has come in handling dissent – but also underscores the impact that a lone voice can have on delaying reviews, and prompting damaging headlines.

What’s Going On With Eliquis and Xarelto at FDA?

A key date was removed from FDA’s tentative advisory committee calendar. But a panel is still expected to review BMS’s anti-clotting agent Eliquis and a new indication for J&J’s Xarelto in ACS.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts